Literature DB >> 7696175

Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression.

D L Miller1, D el-Ashry, A L Cheville, Y Liu, S W McLeskey, F G Kern.   

Abstract

Overexpression of epidermal growth factor receptor (EGFR) is correlated with loss of estrogen receptor and poor prognosis in breast cancer. To investigate this phenomenon, we transfected a cytomegalovirus expression vector directing the expression of EGFR into estrogen receptor-positive MCF-7 breast cancer cells and into a clone of MCF-7 cells previously transfected with transforming growth factor alpha. Cells arising from single clones or pooled polyclonal populations maintained in charcoal-stripped calf serum, a medium devoid of estrogen, overexpressed EGFR. Switching these cells to a medium containing fetal calf serum or charcoal-stripped calf serum plus 17 beta-estradiol resulted in the emergence of a population expressing low EGFR levels. Loss of expression was not a consequence of nonspecific repression of the cytomegalovirus promoter, because expression of the fibroblast growth factor (FGF)-4 complementary DNA in a similar vector was not lost in fetal calf serum. While loss of EGFR overexpression in fetal calf serum was seen at both the protein and mRNA levels, Southern blotting shows that this was not due to loss of the transfected gene. Subclones of a cell population with low EGFR expression were capable of increasing expression upon estrogen withdrawal, demonstrating that the changes in EGFR expression were reversible and suggesting a growth advantage conferred by EGFR overexpression under these restrictive growth conditions. Overexpression of EGFR did not result in loss of ER expression. These results suggest a role for overexpression of EGFR in the growth of estrogen receptor-positive breast cancer cells in the absence of estrogen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7696175

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  28 in total

1.  Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.

Authors:  Chun Chen; William T Baumann; Robert Clarke; John J Tyson
Journal:  FEBS Lett       Date:  2013-08-28       Impact factor: 4.124

2.  Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.

Authors:  Neeraj K Saxena; Dipali Sharma
Journal:  Mol Cell Pharmacol       Date:  2010

Review 3.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

Review 4.  The role of angiogenic growth factors in breast cancer progression.

Authors:  F G Kern; M E Lippman
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

Review 5.  Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells.

Authors:  John J Tyson; William T Baumann; Chun Chen; Anael Verdugo; Iman Tavassoly; Yue Wang; Louis M Weiner; Robert Clarke
Journal:  Nat Rev Cancer       Date:  2011-06-16       Impact factor: 60.716

Review 6.  Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.

Authors:  Meng Zhao; Bhuvaneswari Ramaswamy
Journal:  World J Clin Oncol       Date:  2014-08-10

7.  Inducible expression of FGF-3 in mouse mammary gland.

Authors:  Elly S W Ngan; Zhi-Qing Ma; Steven S Chua; Francesco J DeMayo; Sophia Y Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

8.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

9.  Calmodulin modulates Akt activity in human breast cancer cell lines.

Authors:  Christine M Coticchia; Chetana M Revankar; Tushar B Deb; Robert B Dickson; Michael D Johnson
Journal:  Breast Cancer Res Treat       Date:  2008-06-28       Impact factor: 4.872

10.  TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.

Authors:  Rinath Jeselsohn; William T Barry; Ilenia Migliaccio; Chiara Biagioni; Jin Zhao; Jonas De Tribolet-Hardy; Cristina Guarducci; Martina Bonechi; Naomi Laing; Eric P Winer; Myles Brown; Angelo Di Leo; Luca Malorni
Journal:  Clin Cancer Res       Date:  2016-05-16       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.